Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Estrogen therapy in early menopausal women decreases the risk of coronary heart disease and parenteral, but not oral, estrogen is reported to reduce blood pressure (BP). Progestogens are typically added to estrogens to prevent unopposed endometrial stimulation. The effects of progestogen on BP have been less well studied to date. This study was conducted to explore the impacts of micronized progesterone (MP4) combined with percutaneous estradiol gel (PEG) on hemodynamics in postmenopausal Korean women with grade 1 hypertension. Methods: Fifty-two postmenopausal women (aged 49–75 years) with systolic BP (SBP) of 140–160 mmHg or diastolic BP (DBP) of 90–100 mmHg were randomly assigned for 12 weeks to placebo (n = 16), estrogen therapy (ET) (n = 19) with PEG (0.1 %, 1 g./d), or estrogen + progestogen therapy (EPT, n = 17) with PEG and MP4 (100 mg/ d). The primary endpoint was ambulatory BP and the secondary endpoints were arterial stiffness as brachial–ankle pulse-wave velocity (baPWV) and aortic parameters on applanation tonometry. Results: One woman in the ET group dropped out, so 51 participants were finally analyzed. Outcome measures for ambulatory BP and arterial stiffness were not different between groups. Within-group comparisons showed that EPT significantly decreased daytime heart rate and baPWV: the changes from baseline (mean ± standard deviation) were − 2.5 ± 5.7 bpm (P = 0.03) and − 0.6 ± 1.4 m/s (P = 0.04), respectively. After adjusting for baseline, linear regression analysis revealed a significant difference in the relationship between baseline and 12-week baPWV among groups (P = 0.02). The relationship was significantly different between placebo and ET (P = 0.03) and EPT (P = 0.01), respectively, but not between ET and EPT. Additionally, pooled results of active treatments disclosed that SBP, DBP, PWV, and augmentation index at the aorta were significantly reduced relative to baseline. Conclusions: There was no difference in ambulatory BP between ET and EPT in postmenopausal Korean women with grade 1 hypertension. Further, ET and EPT similarly decreased baPWV from baseline as compared with placebo. MP4 might not adversely influence estrogen effects on ambulatory BP and arterial stiffness. Trial registration: Clinical Research Information Registry, KCT0005405, Registered 22 September 2020 - Retrospectively registered, https://cris.nih.go.kr/cris/search/detailSearch.do?all_type=Y&search_page=L&pageSize= 10&page=1&seq=17608&search_lang=E.
Abstract
Background: Estrogen therapy in early menopausal women decreases the risk of coronary heart disease and parenteral, but not oral, estrogen is reported to reduce blood pressure (BP). Progestogens are typically added to estrogens to prevent unopposed endometrial stimulation. The effects of progestogen on BP have been less well studied to date. This study was conducted to explore the impacts of micronized progesterone (MP4) combined with percutaneous estradiol gel (PEG) on hemodynamics in postmenopausal Korean women with grade 1 hypertension. Methods: Fifty-two postmenopausal women (aged 49–75 years) with systolic BP (SBP) of 140–160 mmHg or diastolic BP (DBP) of 90–100 mmHg were randomly assigned for 12 weeks to placebo (n = 16), estrogen therapy (ET) (n = 19) with PEG (0.1 %, 1 g./d), or estrogen + progestogen therapy (EPT, n = 17) with PEG and MP4 (100 mg/ d). The primary endpoint was ambulatory BP and the secondary endpoints were arterial stiffness as brachial–ankle pulse-wave velocity (baPWV) and aortic parameters on applanation tonometry. Results: One woman in the ET group dropped out, so 51 participants were finally analyzed. Outcome measures for ambulatory BP and arterial stiffness were not different between groups. Within-group comparisons showed that EPT significantly decreased daytime heart rate and baPWV: the changes from baseline (mean ± standard deviation) were − 2.5 ± 5.7 bpm (P = 0.03) and − 0.6 ± 1.4 m/s (P = 0.04), respectively. After adjusting for baseline, linear regression analysis revealed a significant difference in the relationship between baseline and 12-week baPWV among groups (P = 0.02). The relationship was significantly different between placebo and ET (P = 0.03) and EPT (P = 0.01), respectively, but not between ET and EPT. Additionally, pooled results of active treatments disclosed that SBP, DBP, PWV, and augmentation index at the aorta were significantly reduced relative to baseline. Conclusions: There was no difference in ambulatory BP between ET and EPT in postmenopausal Korean women with grade 1 hypertension. Further, ET and EPT similarly decreased baPWV from baseline as compared with placebo. MP4 might not adversely influence estrogen effects on ambulatory BP and arterial stiffness. Trial registration: Clinical Research Information Registry, KCT0005405, Registered 22 September 2020 - Retrospectively registered, https://cris.nih.go.kr/cris/search/detailSearch.do?all_type=Y&search_page=L&pageSize= 10&page=1&seq=17608&search_lang=E.
참고문헌 (33)
- Roth GA, "Global, Regional, and National Burden of Cardiovascular Diseases for 10Causes, 1990 to 2015", J Am Coll Cardiol, 70, pp.1~25 (2017)
- Fuchs FD, "High blood pressure and cardiovascular disease", Hypertension, 75, pp.285~292 (2020)
- Williams B, "2018 ESC", ESH Guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
- Yang WY, "Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes", JAMA, 322, pp.409~420 (2019)
- Oh YS, "Arterial stiffness and hypertension", Clin Hypertens, 24, pp.17~ (2018)
- Benjamin EJ, "Heart disease and stroke statistics-2018 update : a report from the American Heart Association", Circulation, 137, pp.e67~492 (2018)
- "The Korean Statistical Information Service"[URL]
- Abramson BL, "Cardiovascular risk in women : focus on hypertension", Can J Cardiol, 30, pp.553~559 (2014)
- Boardman HM, "Hormone therapy for preventing cardiovascular disease in postmenopausal women", Cochrane Database Syst Rev, 3, pp.CD002229~ (2015)
- Shimbo D, "The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women : results from the Women’s Health Initiative randomized controlled trials", J Hypertens, 32, pp.2071~2081 (2014)
- Mercuro G, "Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension", Am J Cardiol, 80, pp.652~655 (1997)
- Zacharieva S, "Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women", Climacteric, 5, pp.293~299 (2002)
- Scott RT Jr, "Pharmacokinetics of percutaneous estradiol : a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol", Obstet Gynecol, 77, pp.758~764 (1991)
- Rossouw JE, "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause", JAMA, 297, pp.1465~1477 (2007)
- Manson JE, "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials", JAMA, 310, pp.1353~1368 (2013)
- Lee DY, "Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women", Climacteric, 14, pp.492~499 (2011)
- Yamashina A, "Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement", Hypertens Res, 25, pp.359~364 (2002)
- Crilly M, "Indices of cardiovascular function derived from peripheral pulse wave analysis using radial applanation tonometry : a measurement repeatability study", Vasc Med, 12, pp.189~197 (2007)
- Laliberté F, "Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy", Menopause, 18, pp.1052~1059 (2011)
- Renoux C, "Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study", BMJ, 340, pp.c2519~ (2010)
- L’Hermite M, "HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT", Climacteric, 16, pp.44~53 (2013)
- Safar ME, "Interaction between hypertension and arterial stiffness", Hypertension, 72, pp.796~805 (2018)
- Ohkuma T, "Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease : an individual participant data meta-analysis", Hypertension, 69, pp.1045~1052 (2017)
- Zaydun G, "Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase", Atherosclerosis, 184, pp.137~142 (2006)
- Dias AR Jr, "Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women", Climacteric, 11, pp.390~396 (2008)
- Teede HJ, "Placebo-controlled trial of transdermal estrogen therapy alone in postmenopausal women : effects on arterial compliance and endothelial function", Climacteric, 5, pp.160~169 (2002)
- da Costa LS, "Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women", Am J Cardiol, 94, pp.1453~1456 (2004)
- Arruda CG, "Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women", Gynecol Endocrinol, 22, pp.557~563 (2006)
- Fischer GM, "In vivo effects of estradiol on collagen and elastin dynamics in rat aorta", Endocrinology, 91, pp.1227~1232 (1972)
- Vitale C, "Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women", Int J Cardiol, 227, pp.217~221 (2017)
- Ochoa A, "The role of central blood pressure monitoring in the management of hypertension", Curr Cardiol Rep, 20, pp.41~ (2018)
- Williams B, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes : principal results of the Conduit Artery Function Evaluation(CAFE)study", Circulation, 113, pp.1213~1225 (2006)
- Harvey RE, "Aortic hemodynamics in postmenopausal women following cessation of hormone therapy", Physiol Rep, 5, pp.e13535~ (2017)